Last reviewed · How we verify
NCT04588883
Strengthening Families Living With HIV in Kenya
NA trial testing Kuja Pamoja - HIV in ART in 843 participants. Completed in 15 July 2025.
15 July 2025
Quick facts
| Lead sponsor | The University of Texas Medical Branch, Galveston |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 843 |
| Start date | 28 September 2021 |
| Primary completion | 15 July 2025 |
| Estimated completion | 15 July 2025 |
| Sites | 1 location across Kenya |
Drugs / interventions tested
- Kuja Pamoja - HIV
Conditions studied
- ART — all drugs for ART →
- Hiv — all drugs for Hiv →
- Trust — all drugs for Trust →
- Depression, Anxiety — all drugs for Depression, Anxiety →
Sponsor
The University of Texas Medical Branch, Galveston
Who can join
13 and older, any sex, with ART or Hiv. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study seeks to use a group-based microfinance/internal lending model to develop social capital among people with HIV in Kenya. This will create a context to deliver validated curriculum targeting intimate partner violence, positive parenting, agriculture, small business entrepreneurship, group-interpersonal therapy, and other determinants of well-being and ART adherence among people with HIV. The primary outcomes are viral suppression, ART adherence, and common mental disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04588883
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ART
Currently open trials in the same condition.
- NCT07278960 — Enhancing Management Algorithms for Children Conceived Via Assisted Reproductive Technologies · recruiting
- NCT06484335 — RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV · Phase 1 · recruiting
- NCT07263490 — PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) · recruiting
- NCT06334003 — Cardiometabolic Function in Offspring, Mother and Placenta After Assisted Reproductive Technology · recruiting
- NCT06374758 — Accelerated ART Initiation for PWHIV Who Are Out of Care · Phase 4 · recruiting
Other The University of Texas Medical Branch, Galveston trials
Trials by the same sponsor.
- NCT04095260 — Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes. · not yet recruiting
- NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
- NCT07337915 — Improving Sleep In Midlife Women · NA · recruiting
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT07087743 — Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04588883 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston
- Last refreshed: 24 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04588883.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing